Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin vs rivaroxaban prophylaxis for VTE in multiple myeloma
ChiCTR2500096136Phase 3Recruiting
- Sponsor
- Union Hospital
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE) and multiple myeloma (MM) comparing Aspirin group with Rivaroxaban group (2 arms). Primary endpoint: Incidence of venous thromboembolism within 6 months. Started Jan 2025; status: recruiting.
02
Drugs
aspirinrivaroxaban
03
Conditions
venous thromboembolism (VTE)multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500096136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096136.